Key result
Novel truncated apo A-ISasebo mutant causes severe HDL deficiency and reduces LCAT activity to ~30%.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
We identified a 50-year-old Japanese woman with a novel mutation in the apolipoprotein (apo) A-I gene causing high-density lipoprotein (HDL) deficiency. The patient had extremely low HDL cholesterol and apo A-I levels (0.14 mmol/L and 0.8 mg/dL, respectively) but no evidence of coronary heart disease. However, she had bilateral xanthomas of the Achilles tendon, elbow, and knee joint as well as corneal opacities. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of serum followed by immunoblotting revealed that the patient's apo A-I had a lower molecular weight (24,000) than normal apo A-I. A partial gene duplication encompassing 23 nucleotides was found by DNA sequence analysis, resulting in a tandem repeat of bases 333 to 355 from the 5' end of exon 4. This tandem repeat caused a frameshift mutation with premature termination after amino acid 207. The frameshift gives rise to a predicted protein sequence that contains two cysteines. We designated this mutant as apo A-ISasebo. Apo A-ISasebo formed heterodimers with apo A-II and apo E in the patient's plasma and was associated with both the low-density lipoprotein and HDL fractions. The patient's cholesterol esterification rate and lecithin-cholesterol acyltransferase activity were reduced to about 30% of normal, although specific enzyme activity was unaffected, suggesting that it remained functionally normal. In addition, cholesteryl ester transfer activity was reduced to about half of normal. Thus, apo A-ISasebo was associated with complex derangements of lipoprotein metabolism.
No takes yet. Share an insight, caveat, or question.
Moriyama et al. (1996) conducted a case report in High-density lipoprotein (HDL) deficiency (n=1). Apo A-ISasebo mutation (23-nucleotide partial duplication in exon 4 of apo A-I gene) was evaluated on HDL cholesterol, apo A-I levels, and LCAT/cholesterol esterification activity. The novel truncated apo A-ISasebo mutant caused severe HDL deficiency (HDL-C 0.14 mmol/L, apo A-I 0.8 mg/dL) and reduced LCAT activity to ~30% of normal without coronary heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: